

## Technology Advisory Committee C Interests Register

**Topic: Avapritinib for treating advanced systemic mastocytosis [ID3770]**

**Publication Date: 06/11/2024**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
<b>Pedro Saramago Goncalves</b>	Committee Member	Professional Interest	Dr Goncalves is employed with CRD which is the EAG for this appraisal but has not been involved in any work for this appraisal.	06/08/2024	It was agreed that Pedro Saramago Goncalves' declaration would not prevent him from participating in discussions on this appraisal.
<b>Dr Jonathan Lambert</b>	Clinical Expert	Financial Interest	Dr Lambert has received financial remuneration from Blueprint Medicines for advisory boards relating to avapritinib, and for a interview on management of advanced systemic mastocytosis.	06/08/2024	It was agreed that Dr Lambert's declaration would not prevent him from providing expert advice to the committee.
<b>Jess Hobart</b>	Patient Expert	Financial Interests	Jess Hobart declared travel and accommodation expenses covered by Blueprint relating to her attendance to speak to their European staff about life with indolent systemic mastocytosis and an honorarium for prep time and talk.  Jess Hobart also declared she has been a member of the steering	06/08/2024	It was agreed that Jess Hobarts declaration would not prevent her from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<p>committee for a quality-of-life study on systemic mastocytosis that was funded by Blueprint. The UK Mastocytosis Support Group was paid an honorarium for participation (preparation and meeting) in October 2023. This was not specifically about avapritinib.</p> <p>Furthermore, Jess Hobart was a co-author on two posters (ISPOR 2023) on quality of life in systemic mastocytosis that arose from the data from the aforementioned quality-of-life study.</p>		